Clinical Trial Update: Irinotecan as 3rd Line Therapy in Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating irinotecan as third-line therapy for gastric cancer, with the trial status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: Fudan University | Conditions: Stomach Neoplasms | Phase 2 | Status: UNKNOWN